|Mr. Peer Michael Schatz||CEO, MD & Member of Management Board||N/A||N/A||52|
|Dr. Roland Sackers||CFO, MD & Member of Management Board||N/A||N/A||49|
|Mr. Douglas Liu||Sr. VP of Global Operations||N/A||N/A||N/A|
|Mr. John Gilardi||VP of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Jean-Pascal Viola||Head of Corp. Bus. Devel. & Intellectual Property & Litigation and Sr. VP||N/A||N/A||N/A|
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. It offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. The company provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. It also offers instrumentation systems for laboratories. The companys automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories; Modaplex, a multimodal automation system; QIAcube, a sample processing instrument; EZ1 Advanced XL for automated nucleic acid purification; QIAxcel for nucleic acid separation; QIAscout that enables researchers to select and isolate viable single cells; PyroMark, a detection platform that enables real-time analysis and quantification of genetic mutations and DNA methylation patterns; QIAgility, a benchtop instrument; and ESEQuant instruments that enable optical measurement for point of need molecular testing in healthcare and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a partnership with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
QIAGEN N.V.’s ISS Governance QualityScore as of August 1, 2017 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 7; Compensation: 5.